HCA Healthcare shares lag the S&P 500, even as analysts keep a bullish lean

HCA Healthcare’s stock has underperformed the broader market over multiple time frames, according to a recent market recap that framed the question as whether the company’s shares are lagging the S&P 500 for fundamental reasons or simply by timing. As of early June, HCA’s market value was cited at about $82.3 billion, and the shares were down 33.3% from their 52-week high of $556.52. Over the prior three months, HCA was described as having dropped nearly 30%, versus a 10.4% gain for the S&P 500 Index over the same span.

The weakness in the shares was tied largely to how the market reacted to the company’s first-quarter results. HCA shares tumbled 8.8% on April 24 after reporting adjusted EBITDA of $3.80 billion, described as weaker than expected, even as revenue rose about 4% year over year to $19.1 billion. Adjusted EBITDA, a non-GAAP metric (meaning it is not calculated under U.S. GAAP rules), is often used by healthcare operators to track underlying operating performance and compare results across periods.

In its first-quarter release, HCA said it did not experience the typical seasonal volume increase, primarily because of respiratory activity. Respiratory-related admissions were down 42% and respiratory-related emergency room visits were down 32% versus the year-ago period. The company also said a winter storm in January negatively affected patient volumes in certain markets. It added that these unfavorable volume impacts were mostly offset by recognition of certain Medicaid supplemental programs that had not been included in its initial 2026 guidance.

The market focus has also included whether HCA’s 2026 outlook can absorb those headwinds. In the same April 24 update, HCA reaffirmed its 2026 adjusted EBITDA guidance range of $15.55 billion to $16.45 billion, a forecast that had been issued earlier on January 27. The company’s release describes adjusted EBITDA as a key measure it uses internally and provides a forecast table for the year ending December 31, 2026 that includes that guidance range.

Despite the stock’s drawdown, the market recap said analysts remained moderately optimistic. It cited a consensus rating of “Moderate Buy” from 25 analysts and a mean price target of $513.62, which it described as a premium of 38.5% to then-current levels. The takeaway for investors is that the Street’s base case still contemplates recovery or stability in operating conditions, even if near-term volume trends have been choppy.

Part of the reason the stock’s quarter-to-quarter movements matter is the business model. HCA operates a large hospital network and outpatient footprint. In the first-quarter materials, the company said it operated 189 hospitals and approximately 2,600 ambulatory sites of care, including surgery centers and urgent care centers, across 19 states and the United Kingdom. For operators like HCA, patient volumes and payer mix, combined with labor and supply costs, can heavily influence operating results, particularly when seasonal effects shift.

Still, the public materials cited in the market recap and the company’s first-quarter release leave some questions open. The guidance reaffirmation indicates management still expects adjusted EBITDA to fall within its stated range, but neither the market article nor the first-quarter release in the cited excerpts quantifies how much of the January storm and respiratory decline will persist versus normalize in later quarters. In addition, the recap’s comparison to the S&P 500 does not attribute the broader underperformance over the past year to any single driver, meaning investors may need to watch subsequent earnings updates for whether trends match the assumptions embedded in the guidance.